Neurocrine Biosciences, Inc. (NBIX)
Stock Price:
$114.39 USD
-0.35 (-0.31%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
10.67B |
| Revenue (ttm) |
1.01B |
| Net Income (ttm) |
204.79M |
| Shares Out |
93.25M |
| EPS (ttm) |
2.08 |
| PE Ratio |
55.00 |
| Forward PE |
60.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$114.39 |
| Previous Close |
$114.74 |
| Change ($) |
-0.35 |
| Change (%) |
-0.31% |
| Day's Open |
114.06 |
| Day's Range |
113.87 - 115.25 |
| Day's Volume |
332,778 |
| 52-Week Range |
72.14 - 136.27 |
More Stats
| Market Cap |
10.67B |
| Enterprise Value |
10.22B |
| Earnings Date (est) |
Oct 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
93.25M |
| Float |
92.02M |
| EPS (basic) |
2.22 |
| EPS (diluted) |
2.08 |
| FCF / Share |
3.71 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
1.82% |
| FCF Yield |
3.24% |
| Payout Ratio |
n/a |
| Shares Short |
4.82M |
| Short Ratio |
7.88 |
| Short % of Float |
6.12% |
| Beta |
1.30 |
| PE Ratio |
55.00 |
| Forward PE |
60.61 |
| P/FCF Ratio |
30.91 |
| PS Ratio |
10.61 |
| PB Ratio |
12.68 |
| Revenue |
1.01B |
| Operating Income |
274.32M |
| Net Income |
204.79M |
| Free Cash Flow |
345.13M |
| Net Cash |
447.70M |
| Net Cash / Share |
4.80 |
| Gross Margin |
57.73% |
| Operating Margin |
27.28% |
| Profit Margin |
20.40% |
| FCF Margin |
34.32% |
| ROA |
17.26% |
| ROE |
31.15% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (24)
| Buy |
15 |
| Overweight |
1 |
| Hold |
8 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$140.29*
(22.64% upside)
Low
120
Current: $114.39
High
161
Target: 140.29
*Average 12-month price target from 21 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 788 | 451 | 162 | 15.00 | 19.77 | - | 2.92 | 53.14 | 77.41 | 33.50 |
| Revenue Growth | 74.65% | 179.19% | 977.51% | -24.12% | - | - | -94.51% | -31.36% | 131.08% | - |
| Gross Profit | 781 | 446 | 160 | 15.00 | 19.77 | - | 2.92 | 53.14 | 77.41 | 33.50 |
| Operating Income | 72.28 | 36.90 | -131 | -147 | -94.20 | -64.41 | -49.68 | 1.45 | 33.92 | -13.72 |
| Net Income | 37.01 | 21.11 | -143 | -141 | -88.93 | -60.54 | -46.09 | 5.03 | 37.57 | -7.97 |
| Shares Outstanding | 91.63 | 90.24 | 88.09 | 86.71 | 84.50 | 74.58 | 66.99 | 65.62 | 55.18 | 52.82 |
| Earnings Per Share | 0.39 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.67 | -0.15 |
| EPS Growth | 77.27% | - | - | - | - | - | - | -88.06% | - | - |
| Operating Cash Flow | 152 | 101 | -94.33 | -106 | -38.00 | -47.14 | -29.61 | -35.29 | -0.70 | 49.94 |
| Capital Expenditures | -14.74 | -24.78 | -6.93 | -4.10 | -1.93 | -1.57 | -0.51 | -0.94 | -0.51 | 0.02 |
| Free Cash Flow | 137 | 76.59 | -101 | -110 | -39.92 | -48.71 | -30.11 | -36.23 | -1.20 | 49.96 |
| Cash & Equivalents | 674 | 656 | 520 | 312 | 384 | 199 | 150 | 177 | 133 | 133 |
| Total Debt | 496 | 388 | 370 | - | - | - | - | - | - | - |
| Net Cash / Debt | 178 | 268 | 151 | 312 | 384 | 199 | 150 | 177 | 133 | 133 |
| Assets | 1,306 | 993 | 818 | 365 | 475 | 243 | 155 | 196 | 138 | 144 |
| Liabilities | 669 | 512 | 445 | 50.21 | 50.33 | 34.33 | 34.27 | 41.61 | 78.29 | 125 |
| Book Value | 637 | 481 | 372 | 315 | 424 | 209 | 120 | 154 | 60.08 | 19.35 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Neurocrine Biosciences, Inc. |
| Country |
United States |
| Employees |
780 |
| CEO |
Kevin Charles Gorman |
Stock Information
| Ticker Symbol |
NBIX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NBIX |
| IPO Date |
May 23, 1996 |
Description
Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL ? Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.